Download this datacard
Overview
Lobbying Costs
300,000€ - 399,999€
Financial year: Jan 2022 - Dec 2022
Lobbyists (Full time equivalent)
2.25 Fte (3)
Lobbyists with EP accreditation
1
High-level Commission meetings
0
Lobbying Costs over the years
-
Info
Swedish Orphan Biovitrum (Sobi)
EU Transparency Register
232923831740-31 First registered on 07 Jun 2018
Goals / Remit
Sobi is a pharmaceutical company specialized in rare diseases. Specialising in rare diseases, we develop and provide access to innovative treatments in the areas of haematology, immunology and specialty care.
Sobi offers an integrated process, from in-house research and development in protein characterisation, biologics manufacturing and industrialisation, to commercialisation of products for rare diseases. Partnering with stakeholders and facilitating effective and timely rare-disease therapy development, including an extensive and robust distribution network, creates unique opportunities for us to add value to the rare-disease field.Main EU files targeted
Rare disease policies (OMP & Paediatric regulation)
Pharmaceutical Strategy
Pharmaceutical IP
EU HTA
Security of supply
EMA Regulatory Strategy 2025Address
Head Office
Tomtebodavägen 23A
Stockholm
SWEDENEU Office
Swedish Orphan Biovitrum (Belgium)SRL Luchthaven Brussel Nationaal
Zavantem 1K-1930
BELGIUMWebsite
-
People
Total lobbyists declared
3
Employment time Lobbyists 100% 2 25% 1 Lobbyists (Full time equivalent)
2.25
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
1 accreditations were / are live (in bold) for the selected state of 04 May 2023
Name Start date End Date Ms Mihaela VERINGA 26 May 2022 26 May 2023 Complementary Information
None declared
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Companies & groups
-
Networking
Affiliation
Sobi is member of:
- EuropaBio
- EUCOPEMember organisations
https://www.sobi.com/en/trade-association-memberships
-
Financial Data
Interests represented
Promotes their own interests or the collective interests of their members
Closed financial year
Jan 2022 - Dec 2022
Lobbying costs for closed financial year
300,000€ - 399,999€
Major contributions in closed year
None declared
Intermediaries for closed year
Name Amount eucope 0€ - 10,000€ Intermediaries for current year
Name incisive health eucope Closed year Costs
300,000€ - 399,999€
Other financial info
None declared
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
N/A
Communication activities
- European Commission Regulation on health technology assessment and amending Directive 2011/24/EU
- European Commission study on the evaluation of the EU Orphan & Paediatric legislation
- European Commission Pharmaceutical Strategy
- European Parliament/EU Commission EU4Health Programme (particularly for rare diseases, ERNs)Other activities
None declared
- Meetings
Meetings
None declared
- Meetings